Medicina,
Journal Year:
2024,
Volume and Issue:
60(6), P. 1010 - 1010
Published: June 20, 2024
Hepatocellular
carcinoma
is
the
most
common
primary
liver
tumor.
Orthotopic
transplant
one
of
best
treatment
options,
but
its
waiting
list
has
to
be
considered.
Bridge
therapies
have
been
introduced
in
order
limit
this
issue.
The
aim
study
evaluate
if
bridge
advanced
hepatocellular
can
improve
overall
survival
and
reduce
de-listing.
We
selected
185
articles.
search
was
limited
English
articles
involving
only
adult
patients.
These
were
deduplicated
with
incomplete
text
or
irrelevant
conclusions
excluded.
Sorafenib
standard
care
for
increases
without
any
significant
drug
toxicity.
However,
benefit
limited.
combination
transarterial
chemoembolization
+
sorafenib,
instead,
delays
tumor
progression,
although
still
uncertain.
A
few
studies
shown
that
patients
undergoing
radiation
therapy
similar
even
better
outcomes
than
those
sorafenib
alone
rates
histopathologic
complete
response
(89%
had
no
residual
explant).
Also,
combined
radiotherapy
compared
association
associated
a
rate
(24
vs.
17
months).
Moreover,
immunotherapy
revealed
new
encouraging
perspectives.
Combination
showed
results
could
become
gold
as
carcinoma.
Clinical and Molecular Hepatology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 26, 2024
Hepatocellular
carcinoma
(HCC)
is
a
major
global
burden,
ranking
as
the
third
leading
cause
of
cancer-related
mortality.HCC
due
to
chronic
hepatitis
B
virus
(HBV)
or
C
(HCV)
infection
has
decreased
universal
vaccination
for
HBV
and
effective
antiviral
therapy
both
HCV,
but
HCC
related
metabolic
dysfunction
associated
steatotic
liver
disease
(MASLD)
alcohol-associated
(ALD)
increasing.Biannual
ultrasonography
serum
α-fetoprotein
are
primary
surveillance
tools
early
detection
among
high-risk
patients
(e.g.,
cirrhosis,
HBV).Alternative
such
blood-based
biomarker
panels
abbreviated
MRIs
being
investigated.Multiphasic
CT
MRI
standard
diagnosis,
histological
confirmation
should
be
considered,
especially
when
inconclusive
findings
seen
on
cross-sectional
imaging.Staging
treatment
decisions
complex
made
in
multidisciplinary
settings,
incorporating
multiple
factors
including
tumor
degree
dysfunction,
patient
performance
status,
available
expertise,
preferences.Early-stage
best
treated
with
curative
options
resection,
ablation,
transplantation.For
intermediatestage
disease,
locoregional
therapies
primarily
recommended
although
systemic
may
preferred
large
intrahepatic
burden.In
advanced-stage
immune
checkpoint
inhibitor
(ICI)-based
regimen.In
this
review
article,
we
discuss
recent
epidemiology,
risk
factors,
care
continuum
encompassing
surveillance,
staging,
treatments.
Advanced Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 7, 2025
Abstract
Transarterial
chemoembolization
(TACE)
remains
the
gold
standard
for
treating
intermediate‐stage
hepatocellular
carcinoma
(HCC),
yet
faces
great
challenges
in
overcoming
tumor
heterogeneity,
hypoxia‐induced
angiogenesis,
and
metastatic
progression.
The
development
of
advanced
flexible
embolization
materials
marks
a
revolutionary
leap
interventional
therapy,
offering
opportunities
to
revolutionize
precision,
drug
delivery
kinetics,
microenvironment
modulation.
This
comprehensive
review
systematically
examines
paradigm
shift
toward
next‐generation
TACE
technology,
emphasizing
limitations
conventional
approaches
innovations
embolic
agents.
A
detailed
discussion
nano‐flexible
systems
is
presented,
their
unique
coagulation
dynamics,
real‐time
imaging
capabilities,
therapeutic
precision.
delves
into
groundbreaking
strategies
integrating
hypoxia
modulation,
energy
conversion
therapeutics,
sophisticated
engineering.
Clinical
translation
aspects
are
thoroughly
explored,
including
large‐scale
trial
outcomes,
vascular
recanalization
patient‐specific
treatment
optimization.
Looking
forward,
key
frontiers
field
identified:
intelligent
nanocomposite
systems,
synergistic
combination
therapies,
precision
medicine
tailored
individual
biology.
work
not
only
objectively
evaluates
current
progress
but
also
charts
future
research
priorities,
aiming
transform
from
palliative
intervention
platform
ultimately
reshaping
landscape
HCC
patient
care.
JAMA Surgery,
Journal Year:
2024,
Volume and Issue:
159(8), P. 889 - 889
Published: Aug. 1, 2024
Our
website
uses
cookies
to
enhance
your
experience.
By
continuing
use
our
site,
or
clicking
"Continue,"
you
are
agreeing
Cookie
Policy
|
Continue
JAMA
Surgery
HomeNew
OnlineCurrent
IssueFor
Authors
Podcast
Journals
Network
Open
Cardiology
Dermatology
Health
Forum
Internal
Medicine
Neurology
Oncology
Ophthalmology
Otolaryngology–Head
&
Neck
Pediatrics
Psychiatry
Archives
of
(1919-1959)
JN
Learning
/
CMESubscribeJobsInstitutions
LibrariansReprints
Permissions
Terms
Use
Privacy
Accessibility
Statement
2024
American
Medical
Association.
All
Rights
Reserved
Search
Archive
Input
Term
Sign
In
Individual
inCreate
an
Account
Access
through
institution
Purchase
Options:
Buy
this
article
Rent
Subscribe
the
journal
